Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention (Q33339086)

25 July 2017

1 reference

title

Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention (English)

1 reference

respiratory syncytial viruses

25 July 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1403380

23 September 2022

1 reference

W. V. La Via

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1403380

23 September 2022

M. I. Marks

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1403380

23 September 2022

H. R. Stutman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1403380

23 September 2022

language of work or name

English

0 references

publication date

1 October 1992

1 reference

The Journal of Pediatrics

25 July 2017

published in

1 reference

25 July 2017

volume

121

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

503-510

1 reference

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Variation in severity of respiratory syncytial virus infections with subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Epidemiology of acute lower respiratory disease in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Neonatal respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Respiratory syncytial virus: a report of a 5-year study at a children's hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Modes of transmission of respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Use of extracorporeal membrane oxygenation in the treatment of respiratory syncytial virus bronchiolitis: the national experience, 1983 to 1988.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Respiratory syncytial viral infection in infants with congenital heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Respiratory syncytial viral infection in children with compromised immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Pathological changes in virus infections of the lower respiratory tract in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

The Development of Respiratory Syncytial Virus-Specific IgE and the Release of Histamine in Nasopharyngeal Secretions after Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Predictive value of respiratory syncytial virus-specific IgE responses for recurrent wheezing following bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncytial virus. Respiratory syncytial virus is a potent inducer of inhibitor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Interleukin-1-inhibitor activity induced by respiratory syncytial virus: abrogation of virus-specific and alternate human lymphocyte proliferative responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Nebulized albuterol in acute bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Randomized trial of salbutamol in acute bronchiolitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Theophylline therapy in bronchiolitis. A retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Early ribavirin treatment of respiratory syncytial viral infection in high-risk children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Humanised monoclonal antibody to respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

Duration of hospitalization in previously well infants with respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981135-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)81135-7

1 reference

25 July 2017

1 reference